CGIM
AMLX icon

Cannon Global Investment Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Cannon Global Investment Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-25,500
Closed -$90.3K – 72
2025
Q1 		$90.3K Buy
+25,500
New +$90.7K 0.16% 72

Other funds holding AMLX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Cannon Global Investment Management's AMLX Position: Q2 2025 in Review

Cannon Global Investment Management sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2025, closing a stake of 25,500 shares — an estimated $90.3K sold.

Cannon Global Investment Management first reported a position in AMLX in Q1 2025 and held it in 1 quarter. The position peaked at $90.3K in Q1 2025. 131 funds tracked by Wall St. Rank hold AMLX as of Q2 2025.

  • Cannon Global Investment Management reported no remaining Amylyx Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Cannon Global Investment Management sold 25,500 Amylyx Pharmaceuticals shares in Q2 2025, an estimated $90.3K.
  • Cannon Global Investment Management first reported a position in Amylyx Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Cannon Global Investment Management's Amylyx Pharmaceuticals position peaked at $90.3K in Q1 2025.
  • 131 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2025.

Based on Cannon Global Investment Management's 13F filing for Q2 2025, filed 29 Jul 2025.